COVID-19: Resources
COVID-19: Moving Forward Together
02/07/2020 - 13:24
Tocilizumab in COVID-19 - Which Clinical Benefits?
11/06/2020 - 15:04
Lessons for Internists about the Pandemic
11/06/2020 - 11:16Latest News
EFIM General Assembly
Dear EFIM Members,
We are pleased to inform you that the next General Assembly will be organised virtually via the Zoom platform on Friday, 25 September 2020.
Please register on the link below to attend the next General Assembly.
https://us02web.zoom.us/webinar/register/WN_QDA1oMBFTLi4KKOaviQNHQ
We are looking forward to talking to you in September!
IMAGINE the future - a voice of young internists - JAMA
We are pleased to inform you that EFIM IMAGINE Working Group published their paper "IMAGINE the future - a voice of young internists" in JAMA under the title "Sex, Gender, and Precision Medicine". Article can be accessed via JAMA website
here: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2766914?resultClick=1.
Tocilizumab in COVID-19 - Which Clinical Benefits?
Tocilizumab is a recombinant humanized monoclonal IL-6 receptor antibody indicated for the treatment of severe rheumatoid arthritis and other inflammatory disorders.Following clinical observation from China, a series of Italian studies have been carried out to evaluate the off-label use of tocilizumab in COVID-19 patients.
The European Journal of Internal Medicine (EJIM) has recently accepted for publication three articles on the off-label use of tocilizumab in patients with severe COVID-19.
